JD HEALTH
06618
BIDU-SW
09888
JD-SW
09618
ALI HEALTH
00241
BEKE-W
02423
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Cash flow from operating activities | ||||||||||
Earning before tax | -83.59%-16.64M | -342.99%-22.33M | -214.29%-9.06M | 49.30%9.19M | 1,907.59%7.93M | 91.95%6.15M | -77.47%395K | -42.05%3.21M | -90.14%1.75M | -93.82%5.53M |
Profit adjustment | ||||||||||
Interest (income) - adjustment | ---- | -1,460.00%-390K | ---- | 71.59%-25K | ---- | 60.89%-88K | 96.97%-4K | -251.56%-225K | -1,785.71%-132K | -392.31%-64K |
Attributable subsidiary (profit) loss | ---- | --265K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Impairment and provisions: | ---- | 374.00%4.38M | ---- | 272.18%923K | ---- | -87.41%248K | ---- | -88.44%1.97M | -67.65%2.41M | --17.04M |
-Impairment of property, plant and equipment (reversal) | ---- | 43.96%1.03M | ---- | --712K | ---- | ---- | ---- | ---- | ---- | ---- |
-Impairmen of inventory (reversal) | ---- | --3.29M | ---- | ---- | ---- | ---- | ---- | -85.11%2.41M | -66.70%2.41M | --16.16M |
-Impairment of trade receivables (reversal) | ---- | -72.04%59K | ---- | 122.11%211K | ---- | 121.79%95K | ---- | -149.71%-436K | ---- | --877K |
-Other impairments and provisions | ---- | ---- | ---- | ---- | ---- | --153K | ---- | ---- | ---- | ---- |
Revaluation surplus: | ---- | ---1.54M | ---- | ---- | ---- | -63.06%123K | -73.66%133K | 8,425.00%333K | 214.51%505K | -100.31%-4K |
-Other fair value changes | ---- | ---1.54M | ---- | ---- | ---- | -63.06%123K | -73.66%133K | 8,425.00%333K | 214.51%505K | -100.31%-4K |
Asset sale loss (gain): | ---- | ---1.02M | ---- | ---- | ---- | --8K | --8K | ---- | ---- | ---- |
-Loss (gain) from sale of subsidiary company | ---- | ---1.02M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
-Loss (gain) on sale of property, machinery and equipment | ---- | --1K | ---- | ---- | ---- | --8K | --8K | ---- | ---- | ---- |
Depreciation and amortization: | ---- | 8.42%5.15M | ---- | -5.98%4.75M | ---- | 18.59%5.05M | 26.23%2.59M | 26.71%4.26M | 31.64%2.05M | 255.39%3.36M |
-Amortization of intangible assets | ---- | 0.00%279K | ---- | -5.74%279K | ---- | 44.39%296K | 47.00%147K | -11.64%205K | -24.81%100K | 1,684.62%232K |
Financial expense | ---- | 39.11%3.65M | ---- | 32.09%2.63M | ---- | 0.00%1.99M | -33.11%893K | -46.66%1.99M | -27.60%1.34M | 958.81%3.73M |
Special items | ---- | 148.39%75K | ---- | 52.74%-155K | ---- | -45.78%-328K | ---337K | ---225K | ---- | ---- |
Operating profit before the change of operating capital | -83.59%-16.64M | -167.93%-11.76M | -214.29%-9.06M | 31.54%17.31M | 115.66%7.93M | 16.36%13.16M | -53.56%3.68M | -61.79%11.31M | -71.89%7.92M | -67.30%29.59M |
Change of operating capital | ||||||||||
Inventory (increase) decrease | 222.79%7.46M | 34.04%-1.15M | -2.01%-6.08M | 78.97%-1.74M | -200.61%-5.96M | -120.73%-8.27M | -106.80%-1.98M | 331.25%39.9M | 209.65%29.14M | 81.35%-17.25M |
Accounts receivable (increase)decrease | -339.18%-1.57M | 2,382.16%7.81M | 114.41%656K | 94.28%-342K | -736.64%-4.55M | 41.72%-5.97M | 131.10%715K | -154.73%-10.25M | -42.80%-2.3M | 487.10%18.73M |
Accounts payable increase (decrease) | 3,317.87%10.9M | 24.44%-4.89M | 128.87%319K | -177.98%-6.47M | -121.07%-1.11M | 135.12%8.29M | 119.43%5.24M | -311.53%-23.61M | -200.87%-26.99M | 190.10%11.16M |
prepayments (increase)decrease | -228.66%-1.93M | 112.59%2.26M | 9.51%1.5M | -60.10%1.06M | 41.51%1.37M | -71.95%2.67M | -82.25%966K | 274.99%9.51M | 255.16%5.44M | -147.18%-5.43M |
Special items for working capital changes | 92.95%8.87M | ---- | 8.30%4.6M | ---- | --4.24M | ---- | ---- | ---- | ---- | ---- |
Cash from business operations | 187.91%7.1M | -178.60%-7.72M | -519.43%-8.07M | -0.49%9.82M | -77.67%1.93M | -63.24%9.87M | -34.75%8.62M | -27.02%26.85M | -43.13%13.21M | 574.00%36.79M |
Other taxs | -103.94%-170K | 228.57%3.66M | 3,467.19%4.31M | -79.86%-2.85M | 52.06%-128K | 24.43%-1.58M | 3.26%-267K | 89.61%-2.1M | 89.42%-276K | -19,670.59%-20.17M |
Interest received - operating | -23.86%134K | 1,460.00%390K | 2,414.29%176K | -71.59%25K | 75.00%7K | -50.28%88K | -95.24%4K | 176.56%177K | 1,100.00%84K | 392.31%64K |
Interest paid - operating | -41.54%-1.64M | -51.44%-2.42M | -107.90%-1.16M | 23.87%-1.6M | 72.72%-557K | 28.53%-2.1M | 24.93%-2.04M | -117.56%-2.94M | -385.71%-2.72M | -788.16%-1.35M |
Net cash from operations | 214.26%5.42M | -212.72%-6.09M | -480.59%-4.75M | -13.94%5.4M | -80.25%1.25M | -71.46%6.28M | -38.68%6.32M | 43.39%22M | -48.68%10.3M | 291.68%15.34M |
Cash flow from investment activities | ||||||||||
Sale of fixed assets | ---- | ---- | ---- | ---- | ---- | -96.43%3K | -96.43%3K | --84K | --84K | ---- |
Purchase of fixed assets | 62.35%-1.61M | -195.79%-9.27M | -50.74%-4.28M | 49.86%-3.13M | 22.94%-2.84M | 76.23%-6.25M | -43.61%-3.69M | -262.53%-26.29M | -59.31%-2.57M | -14.22%-7.25M |
Purchase of intangible assets | -1,093.33%-179K | 79.95%-80K | 96.13%-15K | -32.12%-399K | -33.79%-388K | 95.47%-302K | -187.13%-290K | -24,607.41%-6.67M | -274.07%-101K | 77.12%-27K |
Acquisition of subsidiaries | ---- | -132.17%-5.71M | -131.60%-5.7M | 73.08%-2.46M | -0.45%-2.46M | 9.02%-9.13M | 75.62%-2.45M | -179.43%-10.04M | -568.00%-10.04M | -321.38%-3.59M |
Other items in the investment business | ---- | -6.90%27K | 7.14%15K | 107.14%29K | --14K | --14K | ---- | ---- | ---- | --1.06M |
Net cash from investment operations | 82.04%-1.79M | -152.08%-15.03M | -75.84%-9.98M | 61.95%-5.96M | 11.65%-5.68M | 63.49%-15.67M | 49.12%-6.42M | -337.32%-42.91M | -301.81%-12.63M | -102.62%-9.81M |
Net cash before financing | 124.66%3.63M | -3,671.07%-21.12M | -232.54%-14.73M | 94.04%-560K | -4,000.00%-4.43M | 55.11%-9.39M | 95.36%-108K | -478.47%-20.92M | -113.75%-2.33M | 143.03%5.53M |
Cash flow from financing activities | ||||||||||
New borrowing | -70.60%3.79M | 240.07%33.34M | 36.74%12.89M | -40.67%9.81M | 151.37%9.42M | -2.93%16.53M | 151.78%3.75M | 122.35%17.03M | -24.61%1.49M | --7.66M |
Refund | -1.74%-14.55M | -162.12%-26.92M | -216.41%-14.31M | -408.62%-10.27M | -171.04%-4.52M | 77.80%-2.02M | 74.76%-1.67M | ---9.1M | ---6.61M | ---- |
Issuing shares | ---- | --35.36M | --35.36M | ---- | ---- | 15.15%11.41M | ---- | --9.91M | --9.91M | ---- |
Dividends paid - financing | ---- | ---- | ---- | ---- | ---- | ---12.66M | ---280K | ---- | ---- | ---- |
Issuance expenses and redemption of securities expenses | ---- | -150.00%-2.83M | ---2.83M | ---1.13M | ---- | ---- | ---- | ---- | ---- | ---- |
Net cash from financing operations | -135.46%-10.93M | 1,665.95%38.44M | 597.74%30.83M | -119.83%-2.46M | 231.68%4.42M | -24.42%12.38M | -68.94%1.33M | 138.59%16.38M | 252.92%4.29M | 14,406.25%6.87M |
Effect of rate | -107.11%-42K | 253.22%642K | 229.32%591K | 30.17%-419K | -63.21%-457K | 46.09%-600K | -149.91%-280K | -4,222.22%-1.11M | 169.26%561K | -89.16%27K |
Net Cash | -145.33%-7.3M | 674.66%17.33M | 161,110.00%16.1M | -200.77%-3.02M | -100.82%-10K | 165.99%2.99M | -37.58%1.22M | -136.58%-4.53M | -89.19%1.96M | 196.12%12.39M |
Begining period cash | 154.21%29.62M | -22.76%11.65M | -22.76%11.65M | 18.84%15.09M | 18.84%15.09M | -30.79%12.69M | -30.79%12.69M | 209.81%18.34M | 209.81%18.34M | -68.11%5.92M |
Cash at the end | -21.40%22.28M | 154.21%29.62M | 93.88%28.34M | -22.76%11.65M | 7.19%14.62M | 18.84%15.09M | -34.63%13.64M | -30.79%12.69M | -10.27%20.86M | 209.81%18.34M |
Cash balance analysis | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.